Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FUJISAWA PLANT CLEARED TO MANUFACTURE ADENOSCAN

Executive Summary

FUJISAWA PLANT CLEARED TO MANUFACTURE ADENOSCAN but approval may be delayed pending the signing of a short-term manufacturing agreement with Medco Research, the holder of the Adenoscan (adenosine) NDA. Medco announced on May 11 that it had "received notification from FDA that Fujisawa's Grand Island [N.Y.] manufacturing facility is now qualified" to produce the cardiovascular stress test agent that will be used as an adjunct to imaging of coronary artery disease and that the company "hopes that an interim manufacturing agreement will be reached with Fujisawa."

Latest Headlines
See All
UsernamePublicRestriction

Register

PS024467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel